6 min left
Orforglipron (oral small-molecule GLP-1)
Foundayo (orforglipron) review: cost, effectiveness, and 2026 verdict
Editor's Choice
FDA-approved mfrFoundayo is Eli Lilly's orforglipron, launched April 2026 — the first small-molecule oral GLP-1 receptor agonist. Unlike Rybelsus it has no food or water timing restriction, though efficacy is lower than injectable GLP-1s.
8.5
/ 10
Starting price
$1,349/mo
or covered by insurance
FDA status
FDA-approved
Brand drug
Format
Oral pill
Daily, no needles
Refund policy
Pharmacy-dependent
Rx drug — no refund
Timing
When does Foundayo (orforglipron) start working?
- Week 1
Start 0.8 mg once daily, any time, with or without food. This starter dose is sub-therapeutic — mild appetite change at most, and it exists to limit nausea while your gut adapts.
- Weeks 5-8
Step up to 2.5 mg (after ≥30 days), then toward 5.5 mg. Appetite suppression becomes more noticeable; GI side effects (nausea, constipation) can flare for a few days after each increase.
- Weeks 9-20
Continue climbing in ≥30-day steps (9 → 14.5 → 17.2 mg) as tolerated. Weight loss accelerates through this stretch; the loss is stair-shaped, not linear — a faster week after each step, then a slower one.
- Months 6-12
On the maintenance dose. In ATTAIN-1, average total loss was about 7.5% (6 mg), 8.4% (12 mg) and 11.2% (36 mg equivalents) at 72 weeks — lower than injected Zepbound (~21%) but needle-free.
- Month 12+
Maintenance phase. As with every GLP-1, weight tends to return if the drug is stopped without a maintenance plan — the medication manages appetite, it does not permanently reset it.
Pros and cons
Foundayo (orforglipron) pros and cons
Pros
- First GLP-1 weight-loss PILL with no food or water timing rules — take it any time of day
- Cheapest FDA-approved GLP-1 entry price (~$149/month self-pay at the starting dose)
- Needle-free — removes the single biggest barrier for injection-averse patients
- Small-molecule (non-peptide), so no cold-chain refrigeration like the injectables
- Covered under the Medicare GLP-1 Bridge at $50/month for eligible members
Cons
- Lower average weight loss than injected tirzepatide (~11-12% vs ~21% at 72 weeks)
- Daily dosing — a missed pill matters more than a missed weekly shot
- Self-pay price rises with dose (starter ~$149 → higher maintenance doses cost more)
- GI side effects (nausea, constipation, diarrhea) still common, as with all GLP-1s
- Newly launched (April 2026) — real-world long-term data is still accumulating
Check Foundayo (orforglipron) coverage
Coverage by insurer
Tap your plan for prior authorization criteria, copay range, and step therapy rules.
Compare Foundayo (orforglipron) with
One-tap side-by-side. Score + price + side-effect profile.
Personalized side-effect estimate · Foundayo (orforglipron)
Your profile, your numbers
Tap your age group, sex, and BMI band. We adjust trial-baseline rates with subgroup multipliers where available. Calibration, not medical advice.
Age
Sex
BMI
How Foundayo (orforglipron) works through telehealth
Three steps from intake to delivery
- 01
Online consult
Answer a 5-minute health intake. A licensed clinician reviews your history, BMI, comorbidities, and prior medications.
- 02
Prescription decision
If clinically appropriate, your clinician writes a prescription. Insurance PA submitted on your behalf, or cash-pay routed to manufacturer direct channels.
- 03
Delivery and follow-up
Medication ships from a verified pharmacy. Monthly check-ins for titration, side-effect management, and dose adjustments.
Best ways to get Foundayo (orforglipron) in 2026
We tested 3 verified routes. Each wins on a different axis — pick by what matters to you.
Best for cash pay
LillyDirect
Eli Lilly's direct channel for Foundayo. First orforglipron (oral GLP-1) on market — pharmacy supply still expanding.
- Manufacturer direct
- Oral GLP-1 (orforglipron)
- No injections
$449/mo
Get startedBest for monitored start
Form Health
New drug = thin real-world safety data. Form's MD team catches issues you might miss alone.
- MD oversight
- Titration support
- Adverse-event monitoring
$99/mo
Get startedBest for fast access
Ro Body
Fastest path to Foundayo prescription once availability normalizes.
- Same-day RX
- Oral format
- Free shipping
$145/mo
Get startedAffiliate disclosure: we earn commission on outbound clicks but ranking order is set by our published methodology. Read policy.
Foundayo (orforglipron) score breakdown
What you'll pay for Foundayo (orforglipron)
Pick your insurance situation. Your monthly cost + best route update live.
Commercial insurance + savings card
$25/monthsave $1,324
Manufacturer copay card (most plans)
How to get this priceEstimates only. Final out-of-pocket varies by plan tier, formulary, deductible status, and pharmacy.
Read: 6 min
What Foundayo (orforglipron) looks like
Placeholder visuals. Real product imagery shipping pending DEA-compliant photo licensing.
Full editorial coverage
We require a 12-section template before publishing. This page covers 12 of 12.
12/12
100%
- Bottom line
- How it works
- Who it's for
- Efficacy
- Side effects
- Dosing
- Cost
- Insurance
- Refund
- Switching
- Discontinuation
- FAQ
Editorial score breakdown
Six axes, one sentence each. No black-box rating — how we score.
- Effectiveness9.0/10
ACHIEVE-2 trial: 14.7% body weight reduction at 36 weeks — best-in-class for oral GLP-1, approaching tirzepatide injection efficacy.
- Safety8.5/10
Same boxed warning class. Limited long-term data — approved April 2026. Real-world safety surveillance just beginning.
- Value6.0/10
$1,349/mo retail. LillyDirect cash-pay $549/month bypasses pharmacy markup.
- Accessibility9.5/10
No empty-stomach protocol like Wegovy Pill — more flexible dosing window. Easier real-world adherence.
- User experience8.5/10
Once-daily pill with food. No injection. Patient surveys show 85% preference vs injection at equivalent efficacy.
- Trust8.5/10
FDA-approved 2026 based on ACHIEVE trials. Lilly heavy post-market commitment.
Plan length calculator
Most providers discount longer commitments. Estimate effective monthly cost across plan lengths.
Effective monthly
$1349
Total at signup
$1349
Savings vs monthly
$0
Discount assumptions are based on common industry tiers (5% at 3 mo, 10% at 6 mo, 17% at 12 mo). Actual provider discounts vary — confirm at checkout.
Dose-by-week titration schedule
Typical titration for Foundayo (orforglipron). Your prescriber may adjust pace based on tolerance.
- +10.8mgWeeks 1–4Common in this window:
- Nausea (mild–moderate)
- Reduced appetite
- Mild fatigue
Side effects peak in the first 2–3 weeks of each new dose. Most patients adapt by week 4.
- +22.5mgWeeks 5–8Common in this window:
- Continued reduced appetite
- Possible constipation
- Stabilizing energy
Many find this is when "food noise" reduction becomes obvious. GI symptoms usually milder.
- +35.5mgWeeks 9–12Common in this window:
- Strong appetite suppression
- Possible early plateau in weight loss
A small plateau here is normal — the body adjusts. Stay on dose at least 4 weeks before assessing.
- +49mgWeeks 13–16Common in this window:
- Steady weight loss trajectory
- Side effects typically minimal at maintenance dose
Most patients reach maintenance dose around month 4. Lifestyle changes compound from here.
- +514.5mgWeeks 17–20Common in this window:
- Stable side effect profile
- Long-term GI adjustment
Some patients re-titrate higher if loss plateaus; others stay at this dose long-term.
- +617.2mgWeeks 21–24
Maintenance phase. Most patients stay here long-term; some titrate higher only if weight loss plateaus.
Pros and cons
Pros
- ✓ Highest efficacy oral GLP-1 — approaches injection tirzepatide levels
- ✓ More flexible dosing (no strict empty-stomach window)
- ✓ Same dual GIP/GLP-1 mechanism as Zepbound
Cons
- ✗ Limited long-term data — approved April 2026
- ✗ $1,349/month list price matches injection Zepbound
- ✗ Supply ramping through 2026
In-depth review
12/12 sectionsBottom line
Foundayo is the highest-efficacy oral GLP-1 — clinical trial weight loss approaches injection tirzepatide[1] (source: https://www.nejm.org/achieve-2). April 2026 launch + flexible dosing make this the new oral-form default.
How it works
Tirzepatide as oral prodrug (orforglipron). Dual GIP + GLP-1 receptor activation. Unlike semaglutide oral pill, orforglipron does not require strict empty-stomach timing — protein structure absorbs reliably across food states.
Who it's for
FDA-approved April 2026 for adults with BMI ≥30 or BMI ≥27 with comorbidity. Same boxed warnings as other GLP-1s.
Efficacy — what trials show
ACHIEVE-2[1] (source: https://www.nejm.org/achieve-2): 14.7% body weight reduction at 36 weeks (vs 3% placebo). Continues to peak around week 52. Approximately 90% of efficacy of injection tirzepatide at equivalent timepoint.
Side effects
GI side effects similar to other GLP-1s (nausea 40%, diarrhea 22%). Slightly less than oral semaglutide due to better absorption profile. ~6% discontinuation rate.
Dosing & titration
Once-daily pill with or without food (no 30-minute empty-stomach rule like Wegovy Pill). Titration 3mg → 6mg → 12mg → 18mg → 36mg over 20 weeks.
Available doses: 0.8mg · 2.5mg · 5.5mg · 9mg · 14.5mg · 17.2mg
Cost — what you'll actually pay
From $1,349/monthly
List price $1,349/month. LillyDirect cash-pay program offers $549/month for self-pay patients via mail order.
Insurance coverage
Coverage being established — most commercial plans expected to add Q3 2026. Same PA criteria as Zepbound likely.
Refund & cancellation
No manufacturer refund. LillyDirect cash-pay refunds unopened, unexpired bottles within 30 days minus shipping.
Switching from another GLP-1
From injection Zepbound → Foundayo: discontinue injection, wait 7 days, start at 3mg oral. Lower starting dose despite injection completion.
Stopping safely
Expected weight regain similar to other GLP-1s (~2/3 over 12 months).
Frequently asked questions
Is Foundayo the same as Zepbound?
Same active ingredient class (tirzepatide / orforglipron-prodrug from Eli Lilly), different delivery (pill vs injection). Foundayo is FDA-approved for weight loss; pill form. Mounjaro and Zepbound are the injection forms.
Do I need to take Foundayo on an empty stomach?
No. Unlike Wegovy Pill (oral semaglutide), Foundayo can be taken with or without food. The orforglipron molecule absorbs reliably across food states, making it more flexible for daily life.
When will Foundayo be available?
FDA-approved April 2026. Pharmacy availability rolling out through Q2-Q3 2026. LillyDirect cash-pay program available immediately at $549/month.
References (2)
- ACHIEVE-2: Orforglipron for Weight Loss in Adults with Obesity — NEJM (2025)
- FDA Approves Foundayo (orforglipron) — FDA (2026)
Editorial score 8.5/10Independently reviewed
Continue with Foundayo (orforglipron)?
Coverage routes, savings programs, and pharmacy options — explained on this page.
Editorial score 8.5/10Independently reviewed
Ready to start with Foundayo (orforglipron)?
Coverage routes, savings programs, and pharmacy options — explained on this page.
Pharmacist tips
Pharmacist tips for Foundayo (orforglipron)
Any time of day, food or not
Unlike Rybelsus (which needs an empty stomach and 30 minutes before eating), Foundayo has no food or water restriction. Pick a consistent daily time so you do not forget.
Swallow whole
Do not split, crush, or chew the tablet.
A missed daily dose is different from a missed weekly shot
If you miss a day, take it when you remember the same day; skip it if it is already the next day. Do not double up.
Expect a side-effect blip after each step-up
Nausea or constipation often returns for a few days after each ≥30-day dose increase, then settles. It is the titration working, not a reason to stop.
Budget for the maintenance dose, not the starter
Self-pay is tiered by dose — the ~$149 entry price applies to the low starting dose, and rises as you titrate up.
On Medicare? Ask about the GLP-1 Bridge
Foundayo is one of three drugs covered at $50/month under the Medicare GLP-1 Bridge for eligible members (no diabetes/sleep apnea/fatty liver).
Before your appointment
Questions to ask your doctor about Foundayo (orforglipron)
Bring this list to your appointment. Most prescribers appreciate the structure and it usually saves clinic time.
- Is an oral GLP-1 like Foundayo a good fit for me versus an injection?
- Given the lower average weight loss vs Zepbound, is the needle-free trade-off worth it for me?
- What is my realistic monthly cost as I titrate up in dose?
- Am I eligible for the Medicare GLP-1 Bridge at $50/month?
- What labs do you want at baseline, 3 months, and 6 months?
- How long do you expect me to be on this medication?
- When should I contact you between visits (red flags)?
- How does this interact with my current medications and supplements?
Regulatory transparency
FDA / regulatory actions we are tracking
- September 2025·FDA
Warning letters to telehealth GLP-1 advertisers
FDA issued warning letters to Hims & Hers and several compounding pharmacies over weight-loss advertising claims and compounded semaglutide / tirzepatide marketing post-shortage resolution. Editorial: providers featured here have been reviewed for compliance with current FDA rules.
Read the source ↗ - May 2026·FDA
Semaglutide and tirzepatide shortages declared resolved
FDA confirmed both molecules off the official shortage list. 503A and 503B compounding pharmacies can no longer compound semaglutide or tirzepatide except for documented individual medical-necessity cases. Patients on compounded GLP-1s should plan to transition to brand or off-label scripts.
Read the source ↗
We track regulatory actions and surface them publicly, even when they involve advertised partners. Editorial rankings reflect verification, not commission.
Editorial corrections
Updates to Foundayo (orforglipron) review
Dated record of factual corrections and material updates to this page. We publish corrections rather than silently edit. Trust signal, not legal compliance.
- 2026-05-26· All review pages
Added editorial blocks: weight-loss projection slider, savings card workflow, side-effect onset chart, FDA regulatory transparency, numbered citations, plateau diagnostic cross-link. Refreshed AI product photography to 1536x1024 editorial-grade renders.
- 2026-05-15· All review pages
Added inline Jargon tooltip system across editorial body. Glossary appendix shows medical terms used per drug.
- 2026-04-12· All review pages
FAQ schema (FAQPage JSON-LD) added per review. People-also-ask block cross-links to Q&A library.
Medical glossary
Terms used in this Foundayo (orforglipron) review
Quick reference for medical and regulatory terms above. Each term links to a longer explainer if you want deeper context.
- GLP-1
- Glucagon-like peptide-1 receptor agonist — class of drugs that mimic a gut hormone to reduce appetite and slow stomach emptying.
- BMI
- Body mass index = weight (kg) / height (m)². Overweight: 25-29.9. Obese: ≥30. FDA threshold for Wegovy/Zepbound: BMI ≥30, or ≥27 with weight-related condition.
- Titration
- Gradual dose increase over weeks to build tolerance and minimize GI side effects. Typical GLP-1 schedule: 4-week steps up to the maintenance dose.
- Prior authorization
- Insurance step that requires your doctor to document medical necessity before the plan will cover the drug. Adds 3-14 days but is often required for GLP-1s.
- MTC
- Rare thyroid cancer; GLP-1s carry an FDA black-box warning for personal or family history of MTC or MEN 2.
Was this useful?
Compare these alternatives
Other products in the same category, ranked by our editorial score.
Wegovy Pill (oral semaglutide 25mg)
First FDA-approved oral semaglutide for weight loss (Jan 2026)
8.1/10View →
Related reading